Therapeutic approaches to the management of dysmetabolic cardiovascular disease

Bibliography

• LAIGHT DW, CARRIER MJ, ANGGARD EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab. Res. Rev (1999) 15:274–282.
   PubMed Web of Science ®Google Scholar
• ZIMMET E BOYKO EJ, COLLIER GR et al.: Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann. NY Acad. Sri (2000) 892:25–44.
   Google Scholar
• EGAN BM, GREENE EL, GOODFRIEND TL: Insulin resistance and cardiovascular disease. Am. j Hyperteris. (2001) 14:116S–125S.
   Google Scholar
• GROOP L, ORHO-MELANDER M: The dysmetabolic syndrome. j Int. Med. (2001) 250:105–120.
   PubMed Web of Science ®Google Scholar
• CALLES-ESCANDON J, GARCIA-RUBI E, MIRZA S et al.: Type 2 diabetes: one disease, multiple cardiovascular risk factors. Cor. Art. Dis. (1999) 10:23–30.
   PubMed Web of Science ®Google Scholar
• RETT K: The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obesity Metab. (1999) l\(Suppl. 1):S8–S16.
   Google Scholar
• GROOP L, FORSBLOM C, LEHTOVIRTA M et al.: Metabolic consequences of a family history of NIDDM (The Botnia Study). Diabetes (1996) 45:1585–1593.
   PubMed Web of Science ®Google Scholar
• ALBERTI K, ZIMMET E CONSULTATION W: Definition, diagnosis and classification of diabetes and its complications. Diabetic Med. (1998) 15:539–553.
   PubMed Web of Science ®Google Scholar
• ZIMMET P, ALBERTI KGMM, SHAW J: Global and social implications of the diabetes epidemic. Nature (2001) 414:782–787.
   PubMed Web of Science ®Google Scholar
• RAO G: Insulin Resistance Syndrome. Am. Fam. Physician (2001) 63:1165–1166.
   Google Scholar
• UKPDS GROUP: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• KING P, PEACOCK I, DONNELLY R: The UKPDS: clinical and therapeutic implications for Type 2 diabetes mellitus. Br PharmacoL (1999) 48:643–648.
   Web of Science ®Google Scholar
• TURNER R, HOLMAN R, STRATTON I et al.: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: (UKPDS 38). Br. Med. J. (1998) 317:703–713.
   PubMed Web of Science ®Google Scholar
• UKPDS GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, DAY C: Thiazolidinediones today. Br. J. Diabetes Vasc. Dis. (2001). 1:7–13.
   Google Scholar
• LAIGHT DW: Therapeutic approaches to insulin resistance. Expert Opin Ther. Patents (2001) 10(11):1703–1709.
   Web of Science ®Google Scholar
• •This review highlights the clinical prospects for novel insulin-sensitising therapies based on recent patent and research literature.
   Google Scholar
• STEPPAN CM, BAILEY ST, BLIAT S et al.: The hormone resistin links obesity to diabetes. Nature (2001) 409:301–312.
   Web of Science ®Google Scholar
• STEARS AJ, BYRNE CD: Adipocyte metabolism and the metabolic syndrome. Diabetes Obesity Metab. (2001) 3:129–142.
   PubMed Web of Science ®Google Scholar
• VIDAL-PUIG A, O'RAHILLY S: Resistin: a new link between obesity and insulin resistance? Clin. EndocrirroL (2001) 55:437–438.
   Web of Science ®Google Scholar
• BERG AH, COMBS TP, SCHERER PE: ACRP30/adiponectin: an adipocytokine regulating glucose and lipid metabolism. Trends EndocrirroL Metab. (2002) 13:84–89.
   PubMed Web of Science ®Google Scholar
• YANG WS, JENG CY, WU TJ etal.: Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in Type 2 diabetic patients. Diabetes Care (2002) 25:376–380.
   Google Scholar
• SUNAYAMA S, WATANABE Y, DAIDA H etal.: Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr. Opin. LipidoL (2000) 11:397–402.
   PubMed Web of Science ®Google Scholar
• SIDHU JS, KASKI JC: Peroxisome proliferator activated receptor y a potential therapeutic target in the management of ischaemic heart disease. Heart (2001) 86:255–258.
   PubMed Web of Science ®Google Scholar
• IMANO E, KANDA T, NAKATANI Y eta].: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephopathy. Diabetes Care (1998) 21:2135–2139.
   PubMed Web of Science ®Google Scholar
• NICHOLAS SB, KAWANO Y, WAKINO S et al.: Expression and function of peroxisome proliferator-activated receptor-yin mesangial cells. Hypertension (2001) 37:722–727.
   PubMed Web of Science ®Google Scholar
• MAUVAIS-JARVIS F, ANDREELLI F, HANAIRE-BROUTIN H et al.: Therapeutic perspectives for Type 2 diabetes mellitus: molecular and clinical insights. Diabetes Metab. (Paris) (2001) 27:415–423.
   PubMed Web of Science ®Google Scholar
• MALAMAS MS, SREDY J, GUNAWAN I et al.: New azolidinediones as inhibitors of protein tyrosine phosphatase 113 with antihyperglycaemic properties. j Med. Chem. (2000) 43:995–1010.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW: Future prospects for the pharmacotherapy of obesity. Future Prescriber (2001) 2:12–14.
   Google Scholar
• PROIETO J et al.: Novel anti-obesity drugs. Expert Opin Investig. Drugs (2000) 9(6):1317–1326.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW, CARRIER MJ, ANGGARD EE: Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res. (2000) 47:457–464.
   PubMed Web of Science ®Google Scholar
• FLANAGAN DEH, MOORE VM, GODSLAND IF et al.: Alcohol consumption and insulin resistance in young adults. Eur. j CM]. Invest. (2000) 30:297–301.
   PubMed Web of Science ®Google Scholar
• CERIELLO A, BORTOLOTTI N, MOTZ E etal.: Red wine protects diabetic patients from meal-induced oxidative stress and thrombosis activation: a pleasant approach to the prevention of cardiovascular disease in diabetics. Eurj Clin Invest. (2001) 31:322–328.
   Google Scholar
• KIRPICHNIKOV D, SOWERS JR: Diabetes mellitus and diabetes-associated vascular disease. Trends Endoctinol. Metab. (2001) 12:225–230.
   PubMed Web of Science ®Google Scholar
• FELDT-RASMUSSEN B: Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab. (2000) 4:64–66.
   Google Scholar
• LAIGHT DW: Nitric oxide therapy for cardiovascular disease. Expert Opin Ther. Patents (2001) 11(6):999–1005.
   Web of Science ®Google Scholar
• •This review showcases the therapeutic potential of modulating NO in the cardiovascular clinic based on recent patent and research literature.
   Google Scholar
• PATEL V, PANJA S, VENKATARAMAN A: The HOPE Study and MICO-HOPE Substudy: effects of ramipril on cardiovascular and macrovascular outcomes in people with diabetes mellitus. Br Diabetes Vasc. Dis. (2001) 1:44–51.
   Google Scholar
• YUSUF S, SLEIGHT P, POGUE J etal.: Effects of an ACE inhibitor, ramipril, on cardiovascular events in high-risk patients. The HOPE Study Investigators. N ErigL Med. (2000) 342:145–153.
   Google Scholar
• YUSUF S: Clinical, public health, and research implications of the HOPE study Eur. Heart J. (2001) 22:103–104.
   Google Scholar
• WAY KJ, KATAI N, KING GL: Protein kinase C and the development of diabetic vascular complications. Diabetic Med. (2001) 18:945–959.
   PubMed Web of Science ®Google Scholar
• VERGES BL: Dyslipidaemia in diabetes mellitus. Diabetes Metab. (1999) 25(S3):32–40.
   PubMed Web of Science ®Google Scholar
• GOLAY A: Are postprandial triglyceride and insulin abnormalities neglected cardiovascular risk factors inType 2 diabetes? Eur. j Clin Invest. (2000) 30(52):12–18.
   Google Scholar
• SUMMERS LKM: Impaired postprandial tissue regulation of blood flow in insulin resistance: a determinant of cardiovascular risk? Atherosclerosis (1999) 147:11–15.
   PubMed Web of Science ®Google Scholar
• BURNETT JR: Therapeutic considerations for postprandial dyslipidaemia. Diabetes Obesity Metab. (2001) 3:143–156.
   PubMed Web of Science ®Google Scholar
• HECK A: Orlistat, a new lipase inhibitor for the management of obesity Nature (2000) 404:672–676.
   PubMed Web of Science ®Google Scholar
• SJOSTROM L: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet (1998) 352:167–172.
   PubMed Web of Science ®Google Scholar
• RDSSNER S: Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Res. (2000) 8:49–61.
   PubMedGoogle Scholar
• HOLLANDER PA etal.: Role of orlistat inthe treatment of obese patients with Type 2 diabetes. Diabetes Care (1998) 21:1288–1294.
   PubMed Web of Science ®Google Scholar
• HEYMSFELD SB etal.: Effects of weightloss with orlistat on glucose tolerance and progression to Type 2 diabetes in obese adults. Arch. Intern. Med. (2000) 160:1321–1326.
   PubMedGoogle Scholar
• HASCHE H, MERTES C, BRUNS R et al: Effects of acarbose treatment in Type 2 diabetic patients under dietary training: A multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr. Metab. (1999) 12:277–285.
   PubMedGoogle Scholar
• HALIMI S, LE BERRE MA, GRANGE V: Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res. Gin Practice (2000) 50:49–56.
   PubMed Web of Science ®Google Scholar
• HANEFELD M, FISCHER S, SCHULZE J et al: Therapeutic potential of acarbose as a first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care (1991) 14:732–737.
   PubMed Web of Science ®Google Scholar
• CITRON HA, TUNBRIDGE FKE, HOLMAN RR: Possible prevention of Type 2 diabetes with acarbose or metformin over 3 years. Diabetologia (2000) 43:A73–290.
   Web of Science ®Google Scholar
• WILD S, BYRNE C: Prevention of Type 2 diabetes and associated cardiovascular disease. Cardiabetes (2001) 1:20–25.
   Google Scholar
• CAMPBELL IW: Antidiabetic drugs present and future: Will improving insulin resistance benefit cardiovascular risk in Type 2 diabetes mellitus? Drugs (2000) 60:1017–1028.
   PubMed Web of Science ®Google Scholar
• UUSITUPA M, LOUHERANTA A, LINDSTROM J et al.: The Finnish Diabetes Prevention Study. Br j Nun: (2000) 83:S137–S142.
   Web of Science ®Google Scholar
• FUJIMOTO WY: Background and recruitment data for the US Diabetes Prevention Program. Diabetes Care (2000) 23:B11–B13.
   Web of Science ®Google Scholar
• LAIGHT DW: Strategies for managing insulin resistance in Type 2 diabetes. Cardiabetes (2001) 1:39–41.
   Google Scholar